8CX9
Structure of the SARS-COV2 PLpro (C111S) in complex with a dimeric Ubv that inhibits activity by an unusual allosteric mechanism
Summary for 8CX9
Entry DOI | 10.2210/pdb8cx9/pdb |
Descriptor | Papain-like protease nsp3, Ubiquitin variant UbV.CV2.1, ZINC ION, ... (6 entities in total) |
Functional Keywords | inhibitor complex, allosteric inhibition, viral protein, viral protein-signaling protein complex, viral protein/signaling protein |
Biological source | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2) More |
Total number of polymer chains | 12 |
Total formula weight | 238772.80 |
Authors | Singer, A.U.,Slater, C.L.,Patel, A.,Russel, R.,Mark, B.L.,Sidhu, S.S. (deposition date: 2022-05-20, release date: 2023-01-25, Last modification date: 2024-11-06) |
Primary citation | van Vliet, V.J.E.,Huynh, N.,Pala, J.,Patel, A.,Singer, A.,Slater, C.,Chung, J.,van Huizen, M.,Teyra, J.,Miersch, S.,Luu, G.K.,Ye, W.,Sharma, N.,Ganaie, S.S.,Russell, R.,Chen, C.,Maynard, M.,Amarasinghe, G.K.,Mark, B.L.,Kikkert, M.,Sidhu, S.S. Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site. Plos Pathog., 18:e1011065-e1011065, 2022 Cited by PubMed Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has made it clear that combating coronavirus outbreaks benefits from a combination of vaccines and therapeutics. A promising drug target common to all coronaviruses-including SARS-CoV, MERS-CoV, and SARS-CoV-2-is the papain-like protease (PLpro). PLpro cleaves part of the viral replicase polyproteins into non-structural protein subunits, which are essential to the viral replication cycle. Additionally, PLpro can cleave both ubiquitin and the ubiquitin-like protein ISG15 from host cell substrates as a mechanism to evade innate immune responses during infection. These roles make PLpro an attractive antiviral drug target. Here we demonstrate that ubiquitin variants (UbVs) can be selected from a phage-displayed library and used to specifically and potently block SARS-CoV-2 PLpro activity. A crystal structure of SARS-CoV-2 PLpro in complex with a representative UbV reveals a dimeric UbV bound to PLpro at a site distal to the catalytic site. Yet, the UbV inhibits the essential cleavage activities of the protease in vitro and in cells, and it reduces viral replication in cell culture by almost five orders of magnitude. PubMed: 36548304DOI: 10.1371/journal.ppat.1011065 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (3.5 Å) |
Structure validation
Download full validation report
